Nanotechnology-based Drug Delivery Market Size & Share - 2032

Nanotechnology-based Drug Delivery Market - By Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective), Global Forecast, 2023 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Global nanotechnology-based drug delivery market 3600&nbsp;synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Technology trends

2.1.4&nbsp;&nbsp;&nbsp; Application trends

Chapter 3&nbsp;&nbsp;&nbsp;Nanotechnology-based Drug Delivery Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing prevalence of chronic conditions

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing preference for personalized medicines

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing advancements in nanomaterials

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Stringent regulatory policies

3.2.2.2&nbsp;&nbsp;&nbsp;High cost of nanotechnology drug delivery technique

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By technology

3.3.2&nbsp;&nbsp;&nbsp; By application

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Recent advancement and future prospects

3.7&nbsp;&nbsp;&nbsp; FDA-approved nanotechnology-based products and clinical trials

3.8&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Company positioning matrix

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Nanotechnology-based Drug Delivery Market Size and Forecast, By Technology (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by technology

5.2&nbsp;&nbsp;&nbsp; Nanocrystals

5.3&nbsp;&nbsp;&nbsp; Nanoparticles

5.4&nbsp;&nbsp;&nbsp; Liposomes

5.5&nbsp;&nbsp;&nbsp; Micelles

5.6&nbsp;&nbsp;&nbsp; Other technologies

Chapter 6&nbsp;&nbsp;&nbsp;Nanotechnology-based Drug Delivery Market Size and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Neurology

6.3&nbsp;&nbsp;&nbsp; Oncology

6.4&nbsp;&nbsp;&nbsp; Cardiovascular/Physiology

6.5&nbsp;&nbsp;&nbsp; Anti-inflammatory/Immunology

6.6&nbsp;&nbsp;&nbsp; Anti-infective

6.7&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Nanotechnology-based Drug Delivery Market Size and Forecast, By Region (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by region

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; France

7.3.4&nbsp;&nbsp;&nbsp; Spain

7.3.5&nbsp;&nbsp;&nbsp; Italy

7.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; Japan

7.4.2&nbsp;&nbsp;&nbsp; China

7.4.3&nbsp;&nbsp;&nbsp; India

7.4.4&nbsp;&nbsp;&nbsp; Australia

7.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

7.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

8.2&nbsp;&nbsp;&nbsp; BlueWillow Biologics

8.3&nbsp;&nbsp;&nbsp; Camurus AB

8.4&nbsp;&nbsp;&nbsp; Celgene, Inc.

8.5&nbsp;&nbsp;&nbsp; Cristal Therapeutics

8.6&nbsp;&nbsp;&nbsp; Johnson and Johnson

8.7&nbsp;&nbsp;&nbsp; Merck and Co., Inc

8.8&nbsp;&nbsp;&nbsp; Nanobiotix

8.9&nbsp;&nbsp;&nbsp; NanoCarrier Co. Ltd.

8.10&nbsp;&nbsp;&nbsp; NanOlogy LLC

8.11&nbsp;&nbsp;&nbsp; Novartis International AG

8.12&nbsp;&nbsp;&nbsp; Starpharma Holdings Limited 
&nbsp;

Nanotechnologybased Drug Delivery Market

Get a free sample of this report